Thalia S Field
Thalia S Field, MD is an expert in Neurology at Vancouver General Hospital (Canada). As of October 2026, ScienceLeadR ranks Thalia S Field in the top 1% of experts worldwide for Cerebrovascular Disorders, Brain Ischemia and Embolism and Thrombosis. Thalia S Field has authored 353 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 3 of them ongoing. SLR score: 1,557 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2002 - 2026
Number : 353
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Feasibility of multi-domain data acquisition in patients at risk for hypoxic-ischemic brain injury following cardiac arrest: a prospective cohort study. PMID 42787924 — brain injuries, serum, brain, multiple chronic conditions, cohort studies, biomarkers, electroencephalography, heart arrest | Resusc Plus | 2026 | 0 |
| Health Disparities, Inequalities and Inequities in Stroke Care: A Global Critical Integrative Review (1991-2024). PMID 42786611 — heart diseases, stroke, sex, social identification | J Am Heart Assoc | 2026 | 0 |
| Endovascular Thrombectomy for Cerebral Venous Thrombosis: Current Status and Future Directions. PMID 42591073 — venous thrombosis, cerebrovascular disorders, sinus thrombosis, intracranial, therapeutics, thrombosis, thrombectomy | Semin Intervent Radiol | 2026 | 0 |
| Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage: A Placebo-Controlled Trial. PMID 42558067 — brain injuries, cerebral hemorrhage, hemorrhage, colchicine, neuroimaging, pharmaceutical preparations, cerebrovascular circulation, cerebrovascular disorders, medication adherence, risk factors, random allocation | Stroke | 2026 | 0 |
| Investigation and management of breakthrough ischemic stroke in anticoagulated patients with atrial fibrillation. PMID 42508832 — ischemic stroke, stroke, atrial fibrillation, therapeutics, direct-acting oral anticoagulants | BMJ Top journal | 2026 | 3 |
Clinical Studies 26
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 5
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| NoNO 42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy NCT06403267 — safety, ischemic stroke, stroke, powders, neuroprotective agents, neuroprotection, reperfusion, cerebral infarction, thrombectomy, ischemia, male | Phase 2 | Recruiting | 2024 |
| ACT GLOBAL THROMBOLYSIS (ACT WHEN 001) Domain Within the ACT GLOBAL Adaptive Platform Trial NCT06352632 NCT06320431 — ischemic stroke, stroke, multiple chronic conditions, body weight, tenecteplase, therapeutics, thrombectomy, direct-acting oral anticoagulants | Phase 3 | Recruiting | 2024 |
| EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE MeVO Trial) NCT05151172 — safety, blood, ischemic stroke, stroke, pharmaceutical preparations, blood pressure, fibrinolytic agents, intracranial thrombosis, coagulants, therapeutics, thrombosis, thrombectomy, blood vessels | N/A | Active not recruiting | 2022 |
LeadR Networks
Main global connection map